Icotinib hydrochloride

Other name

-

International/Other brands

Icotinib hydrochloride

Groups

Approved

Structure

Prescription products

Target

EGFR

Description

Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

Indications

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.

Other indications

-

Mechaism of action

-

Absorption

Bioavailability = 52%

Metabolism

Hepatic (mainly CYP3A4, less CYP1A2)

Toxicity

The most common toxicities reported are skin-related events and diarrhea.